Eli Lilly sponsored NeuroTech Ontario Showcase & Public Talk on Sep 27, 2016  

Overview

Update
Acquisitions
12 Acquisitions
IPO / Stock
Went Public on Jan 13, 1978 / NYSE:LLY
Headquarters:
Indianapolis, IN
Description:
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
Categories:
Biotechnology, Medical
Website:
http://www.lilly.com
Social:

Company Details

Update
Founded:
January 1, 1876
Contact:
1(317)276-2000
Employees:
10k + | 28 in Crunchbase

Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Products Neurosciences products, include: Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Cymbalta, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia; Strattera, for the treatment of attention-deficit hyperactivity disorder in children, adolescents and adults; Prozac, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder; and Symbyax, for the treatment of bipolar depression. Endocrinology products, include: Humalog, Humalog Mix 75/25, and Humalog Mix 50/50tm, for the treatment of diabetes; Humulin, for the treatment of diabetes; Byetta, for the treatment of type 2 diabetes; Actos, for the treatment of type 2 diabetes; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; and Humatrope, for the treatment of human growth hormone deficiency and idiopathic short stature.

Investments (11)

DateInvested InRoundPartner(s)
Jan, 2016$17M / Series A
Jan, 2016$61.5M / Series A
Jan, 2016$48M / Series A
Nov, 2015£4.45M / Series A
Jul, 2015$320M / Series A
May, 2015$3M / Series B (Lead)
Dec, 2013$26M / Series D
Jun, 2012$20M / Venture (Lead)
May, 2008$6.5M / Series B
Mar, 2004$10.67M / Series B
Jan, 2003$30M / Series C

Current Team (28)

Update

Sub Organizations (3)

Update

Offices/Locations (1)

Update
  • Headquarters

    Lilly Corporate Center

    Indianapolis, IN 46285

    USA

Images (1)

Update

Add Funding Rounds

Add Products

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos